Cost-effectiveness of combination therapy for treatment of benign prostatic hyperplasia: A model based on the findings of the Combination of Avodart and Tamsulosin trial

BJU International

Volumn 109, Issue 5, 2012, Pages 731-738

  Bjerklund Johansen, Truls E ^a   Baker, Timothy M ^b   Black, Libby K ^c  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNITED BIOSOURCE CORPORATION   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

benign prostatic hyperplasia; combination therapy; dutasteride; economic evaluation; tamsulosin

Indexed keywords

DUTASTERIDE; TAMSULOSIN;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE SEVERITY; DRUG COST; ECONOMIC EVALUATION; HEALTH CARE COST; HEALTH STATUS; HUMAN; INCREMENTAL COST EFFECTIVENESS RATIO; MALE; MONOTHERAPY; NORWEGIAN ECONOMIC MODEL; PATIENT CARE; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SENSITIVITY ANALYSIS; TRANSURETHRAL RESECTION; TREATMENT INDICATION; URINE RETENTION;

5-ALPHA REDUCTASE INHIBITORS; ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; AGED; AZASTEROIDS; COST-BENEFIT ANALYSIS; DRUG THERAPY, COMBINATION; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; PROSTATIC HYPERPLASIA; SULFONAMIDES;

EID: 84857355787     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2011.10511.x     Document Type: Article

References (18)

1. Desgrandchamps F, de la Taille A, Azzouzi AR, et al,. Management of non-complicated BPH: proposition of a renewed decision tree. World J Urol 2006; 24: 367-70 (Pubitemid 44304931)
2. Madersbacher S, Alivizatos G, Nordling J, et al,. EAU 2004 guidelines on assessment, therapy and follow-up of men with lower urinary tract symptoms suggestive of benign prostatic obstruction (BPH guidelines). Eur Urol 2004; 46: 547-54 (Pubitemid 39345720)
3. Spatafora S, Conti G, Perachino M, et al,. Evidence-based guidelines for the management of lower urinary tract symptoms related to uncomplicated benign prostatic hyperplasia in Italy: updated summary. Curr Med Res Opin 2007; 23: 1715-32 (Pubitemid 47122181)
4. Speakman MJ, Kirby RS, Joyce A, Abrams P, Pocock R,. Guideline for the primary care management of male lower urinary tract symptoms. BJU Int 2004; 93: 985-90 (Pubitemid 38758619)
5. Roehrborn CG, Siami P, Barkin J, et al,. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study. J Urol 2008; 179: 616-21; discussion 21
6. Roehrborn CG, Siami P, Barkin J, et al,. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57: 123-31
7. Issa MM, Runken MC, Grogg AL, Shah MB,. A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride. Am J Manag Care 2007; 13 (Suppl. 1): S10-6
8. Johansen TEB, Istad JA,. Long-term cost analysis of treatment options for benign prostatic hyperplasia in Norway. Scand J Urol Nephrol 2007; 41: 124-31 (Pubitemid 46598103)
9. McConnell JD, Roehrborn CG, Bautista OM, et al,. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003; 349: 2387-98 (Pubitemid 37542987)
10. Baladi JF, Menon D, Otten N,. An economic evaluation of finasteride for treatment of benign prostatic hyperplasia. Pharmacoeconomics 1996; 9: 443-54 (Pubitemid 26141901)
11. Cher DJ, Miyamoto J, Lenert LA,. Incorporating risk attitude into Markov-process decision models: importance for individual decision making. Med Decis Making 1997; 17: 340-50 (Pubitemid 27282036)
12. World Health Organization (WHO). Mortality and Burden of Disease, Life Tables 2008 [Internet]: Global Health Observatory (GHO). Available at:. Accessed May 2010
13. Ackerman SJ, Rein AL, Blute M, et al,. Cost effectiveness of microwave thermotherapy in patients with benign prostatic hyperplasia: part I-methods. Urology 2000; 56: 972-80
14. Fenter TC, Davis EA, Shah MB, Lin PJ,. Dutasteride vs finasteride: assessment of differences in acute urinary retention rates and surgical risk outcomes in an elderly population aged > or = 65 years. Am J Manag Care 2008; 5 (Suppl. 2): S154-9
15. Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS,. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care 2008; 46: 349-56
16. Hirth RA, Chernew ME, Miller E, Fendrick AM, Weissert WG,. Willingness to pay for a quality-adjusted life year: in search of a standard. Med Decis Making 2000; 20: 332-42 (Pubitemid 30479101)
17. Eichler HG, Kong SX, Gerth WC, Mavros P, Jonsson B,. Use of costeffectiveness analysis in health-care resource allocation decisionmaking: how are cost-effectiveness thresholds expected to emerge? Value Health 2004; 7: 518-28. (Pubitemid 39390832)
18. The National Board of Health and Welfare. Socialstyrelsens riktlinjer för hjärtsjukvård. Beslutsstöd för prioriteringar. 2004.